JSM Sexual Medicine

Expression and Differential Regulation of NR5A1 or SF1 in Harderian Gland of Hamster

Research Article | Open Access
Article DOI :

  • 1. National Polytechnic Institute, National School of Biological Sciences, Environmental Toxicology Laboratory, Mexico
  • 2. National Polytechnic Institute, National School of Biological Sciences, Immunochemistry Laboratory I, Mexico
+ Show More - Show Less
Corresponding Authors
Luis Alberto García-Avila, Av. Wilfrido Massieu s/n, Zacatenco Professional Unit, Mexico City, CP 07738, Mexico

A complex of multiple enzymes carries out the steroidogenic process; among them is the acute steroidogenesis regulatory protein (StAR) which controls the amount of cholesterol supply that enters the inner membrane of the mitochondria. This cholesterol is the precursor for the biosynthesis of steroid hormones [1]. The first reaction in this biosynthesis is the conversion of cholesterol to pregnenolone by the action of the cytochrome P450 side-chain cleavage enzyme (P450scc; CYP11A1). This enzyme resides on the matrix side of the inner mitochondrial membrane. Existing pregnenolone in mitochondria is converted into progesterone and other steroids in microsomal compartments of the cell [2].

Nuclear receptor subfamily 5 group A member 1 (NR5A1), also called steroidogenic factor 1 (SF1), has been identified as a critical factor in the expression of several steroidogenic enzymes, including cytochromes P450 such as CYP11A1, CYP17A1, CYP21A2, CYP11B1, CYP11B2, 3β-hydroxysteroid dehydrogenase, and the StAR protein [3]. It is an essential transcription factor in the regulation of various genes crucial for normal endocrine function, as well as for the reproductive physiology of the individual. The gene encoded by NR5A1 is highly expressed in steroidogenic tissues, where it controls several steps of gonadal and adrenal development [4]. Complete loss of function of NR5A1 in mice has been shown to result in dysgenesis of the gonads and adrenal primordia via apoptosis. However, the mechanism by which this apoptosis occurs is unknown [5]. In addition, steroidogenic organs, structures, and functions in nonsteroidogenic tissues where NR5A1 is also expressed (such as the pituitary gland, ventromedial hypothalamic nucleus, and spleen) are also affected in mice, indicating that this factor is essential in the differentiation, proliferation, and survival of the cells where it is expressed [6,7].

The high level of expression of the NR5A1 gene in the male gonad after differentiation has been shown to play a vital role in gonadal differentiation, mainly regulating the TP53 pathway during development, which is essential for the cell survival of fetal Sertoli cells, and controlling the cell cycle of Sertoli cells, during differentiation [8]. In addition, mutations in NR5A1 are associated with premature ovarian failure in humans [9].

Johann Jacob Harder first described the Harderian gland (HG) in 1694, which is present in most terrestrial vertebrates and responsible for eyeball lubrication [10]. This gland is very well developed in rodents (rats, mice, hamsters, gerbils, and guinea pigs) and occupies a considerable part of the posterior area of the eyeball. In rodents, HG contains many lipids and porphyrins secreted via this pipeline [11].

In particular, HG from the Syrian hamster (Mesocricettus auratus) has been widely studied due to its marked sexual dimorphism; these dimorphic characteristics are observed in histology and lipid, porphyrin, and melatonin content. The concentration of porphyrins is much higher in females than in males, in addition to the fact that females have high melatonin levels.

This HG secretory activity seems to be regulated by steroids and the sexual dimorphism shown in the Syrian hamster [12]. Although some studies have suggested that HG can be classified as steroidogenic [13], no studies confirm the expression of NR5A1/SF1 in hamster HG, the experimental cDNA sequence, or the deduced amino acid sequence of this factor of transcription have been reported. In this study, we focus on determining the experimental sequence of the cDNA corresponding to NR5A1/ SF1, its expression in HG, and whether it presents dimorphic differences, being affected by sex steroids.


Total RNA extraction

Total RNA was extracted from the hamster liver, testis, and ovary, using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The tissue was homogenized and incubated for 5 min at room temperature, then 200 μl of chloroform was added for each ml. of the initial solution. The samples were shaken vigorously and centrifuged at 12,000 xg for 15 min at 4 °C. The aqueous phase was extracted to add 500 μl of isopropanol for each ml of the initial solution. This mixture was incubated for 10 min at room temperature after time and was centrifuged at 12,000 xg for 10 min at 4 °C. The supernatant was discarded, while the precipitate was washed with 1 ml of 75% ethanol, and then centrifuged at 12,000 xg for 10 min and 4 °C, the supernatant was discarded, and the RNA was allowed to dry at room temperature. Total RNA was dissolved in nuclease-free water, and the purity and concentration were evaluated at 260/280 nm in a spectrophotometer (Beckman DU 650; Fullerton, CA, USA).

Complementary DNA synthesis

Complementary DNA (cDNA) was synthesized with SuperScrip First-Strand cDNA (Invitrogen, Carlsbad, California, USA). For the reaction, a mixture of RNA (3-5 μg), one μl of dNTP mix, and one μl of oligo dT (0.5 μg) were made and brought to a final volume of 10 μl with DEPC-treated water. The mixture was incubated for 5 min at 65 °C and then placed on ice for 1 min. In a separate tube, another mix was prepared to contain 2 µl of 10X RT solution, 4 µl of 25 mM MgCl2, 2 µl of 0.1 M DTT, and 1 µl of RNaseOUT (40 U/µl). The nine μl of this mixture were added to the first reaction and mixed carefully, to be later incubated for 2 min at 42°C, and at the end of this incubation, one μl of SuperScript II RT was added. It was incubated again for 50 min at 42 °C followed by 15 min at 70°C. At the end of the reaction, one μl of RNase H was added and incubated for 20 min at 37°C. The reaction was stored at −20°C until its use in PCR.

Synthesis of the 5’ and 3’ ends of the cDNA

The cDNA corresponding to the 5’ and 3’ ends was synthesized using the SMARTer RACE 5’/3’ kit (Takara Inc, USA). For each of the reactions, a buffer mixture was prepared to contain four μl of 5X First-Strand, 0.5 μl of DTT (100mM), and one μl of dNTPs (20 mM) for a total volume of 5.5 μl each. On the other hand, in the case of the 5’ reaction, 1 μg of RNA was mixed with one μl of 5’-CDS Primer A and brought to a total volume of 11 μl with sterile water. For the 3’ reaction, 1 μg of RNA and one μl of 3’- CDS Primer A were mixed and brought to 12 μl with sterile water. These last two mixtures were incubated for 3 min at 72° C, followed by another at 42 °C for 2 min, to denature the RNA. A third mix was prepared using the 5.5 μl of the first prepared buffer, to which was added 0.5 μl of RNase Inhibitor (40 U/μl) and two μl of SMARTScribe Reverse Transcriptase (100 U), resulting in a total volume of 8 μl for each reaction, which was added to the denatured RNAs, leaving a 20 μl volume reaction, which was incubated for 90 min at 42 °C and 10 min at 70°C. The reaction products were diluted in 90 μl of Tris-EDTA pH 7.6.

Oligonucleotide design

The region corresponding to NR5A1/SF1 to amplify oligonucleotides was designed using the Integrated DNA Technologies, Inc. “PrimerQuest Tool” online tool (https://www. idtdna.com/Primerquest/Home/Index). The predicted sequence for the NR5A1/SF1 cDNA of Mesocrisetus auratus available in the GenBank of the National Center for Biotechnology Information (NCBI) was used. The oligonucleotides were designed to amplify an internal region of the NR5A1/SF1 sequence. In contrast, for the extreme regions, oligonucleotides were designed to amplify regions within 300 base pairs (bp) of both the 5’ end and the end. 3’, amplified using the rapid amplification of cDNA ends (RACE) technique.

Polymerase Chain Reaction (PCR)

Amplification of the central region corresponding to NR5A1/ SF1 was performed using two pairs of oligos SF1-1PF, SF1-1PR, and SF1-2PF, SF1-2PR for the amplification reaction were mixed in one tube, four μl of 5X buffer. , 0.5 μl of dNTPs (10 mM), 0.1 μl of GoTaq polymerase, eight μl of MgCl2 (25mM), four μl of DMSO and eight μl of cDNA and with the conditions of 94 °C for 3 min of initial denaturation, 30 cycles with denaturation temperature at 94° for 30 sec, alignment 60°C for 30 sec, an extension of 72°C for 30 sec, followed by a final extension of 72°C for 3 min. The reaction products were visualized in a 1% agarose gel stained with ethidium bromide to purify the observed bands.

Rapid amplification of cDNA ends (RACE)

The 5’ and 3’ ends were amplified using the SMARTer RACE 5’/3’ kit (Takara Bio USA, Inc.). Different mixtures were made containing 12.5 μl of 2X SeqAmp buffer solution., 0.5 μl of SeqAmp Polymerase, 2.5 μl of 10X Universal Primer Mix (UPM), 0.5 μl of 20 mM gene-specific oligonucleotide (GSP), and three μl of 5’ or 3’ cDNA as appropriate and completed with sterile water to a final volume of 25 µL. The reaction was carried out with 35 cycles of 94 °C for 30 sec, 68 °C for 30 sec, and 72°C for 3 min. The reaction products were visualized on a 1% agarose gel to purify the bands.

DNA purification on agarose gel

DNA purification in agarose gel was also performed using the E.Z.N.A® gel extraction kit (Omega Bio-tek, Inc. USA). The fragment of the gel containing the DNA band was excised and placed inside a 1.5 ml conical tube, where 500 μl of XP2 Binding was added, to be incubated at 60°C until the gel was completely dissolved, never exceeding 7 min of incubation. The mini-column was placed inside a 2 ml collection tube, and the DNA/agarose solution was added. The column was centrifuged at 10,000 xg for one minute, and the filtrate was discarded. 300 μl of XP2 Binding buffer was added and centrifuged at maximum speed (≤ 13000 xg) for 1 min, and the filtrate was discarded. 700 μl of SPW buffer solution, previously diluted with 100 ml of 100% ethanol, was added and centrifuged at maximum speed for 1 min, and the filtrate was discarded. This last washing step was repeated with SPW buffer. The empty column was centrifuged at maximum speed to eliminate any traces of alcohol. Then the column was transferred to a new collection tube, and 30 μl of elution buffer was added to the center of the column, avoiding touching the membrane, and incubated for 1 min and centrifuged at maximum speed for 1 min. Five μl of the purified DNA was used to run it on a 1% agarose gel. It was observed in a photo documenter (Molecular Imager ChemiDoc XRS+ with Image Lab Software, BioRad, Hercules, CA, USA).


Sequencing was performed using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Austin, TX, USA), with which PCR amplification of the product to be sequenced was performed. For said reaction, a mixture was made which contained one μl of BigDye Solution 5X, two μl of BigDye Terminator reaction mix, one μl of specific oligonucleotide (20 mM), five μl of DNA (5-20 ng) and was completed with water to a total volume of 10 µL. The reaction was carried out under the following conditions: 1 cycle at 96 °C for 1 min, 35 cycles at 96 °C for 10 sec, 50 °C for 5 sec, and 60 °C for 4 min. At the end of the reaction, the samples were purified using the BigDye XTerminator kit (Applied Biosystems, Austin, TX, USA). 45 μl of SAM solution and ten μl of BigDye Xterminator solution were added to each sample and shaken for 30 min. After this time, the samples were centrifuged at 3000 xg for 2 min. The supernatant was removed and placed in another tube. These samples were analyzed by capillary electrophoresis in an ABI PRISM 310 Genetic Analyzer sequencer (Applied Biosystems, Foster City, CA, USA).


RNA extraction

RNA extraction from the testicle and ovary was performed using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA), the integrity of the RNA was observed in a 1% agarose gel, in which the full bands could be observed, corresponding to the 28S and 18S ribosomal subunits. Once the integrity of the RNA was corroborated, 1μg of it was used to carry out the reverse transcription reaction (RT) to obtain the cDNA.

Oligonucleotide design

Two pairs of oligonucleotides were designed using the “PrimerQuest Tool” online tool (Integrated DNA Technologies, Inc.) to amplify a core region of NR5A1/SF1. The sequence predicted for Mesocrisetus auratus NR5A1/SF1 cDNA is available in the GenBank of the National Center for Biotechnology Information and was used for design. The first pair of oligonucleotides, SF1-1PF and SF1-1PR, comprised an expected amplicon of 1000 bp, and the second pair of oligonucleotides, SF1-2PF and SF1-2PR, was expected to have an amplicon of 1014 bp.

Polymerase chain reaction

The polymerase chain reaction (PCR) was performed using hamster ovary and testis cDNA. For both cDNAs, three reactions were performed with a pair of oligonucleotides. These three reactions were carried out at different hybridization temperature gradients: 58° C, 60° C, and 62°C.

Considering the obtained amplifications at different gradients and cDNAs, it was decided to use the ovary cDNA, the oligonucleotides SF1-2PF and SF1-2PR, with a hybridization temperature of 58°C, to perform four reactions, which were run in a 1% agarose gel. Once the bands that possibly correspond to the central fragment of SF1/NR5A1 were identified, these bands were excised from the gel and purified by electro-elution. The purified product was rerun on a 1% agarose gel to observe the amount and integrity of the recovered fragment. Once the quality of the purified fragment was checked, it was labeled and stored until it was sequenced.

Rapid amplification of cDNA ends (RACE)

To perform the 5’ and 3’ RACE reaction, cDNA from hamster testis and the SMARTer RACE 5’/3’ kit (Takara Bio USA, Inc.) were used. For each end, an amplification reaction was made with each designed oligonucleotide. These reactions were run on an agarose gel to observe the reaction products. Of the reactions carried out, it was only possible to observe an appropriate amplification with the oligonucleotide 5R2 of the possible fragment belonging to the 5’ region of SF1/NR5A1. In the case of oligonucleotides 3R1 and 3R2 (corresponding to the 3’ region), a slight amplification was observed, so it was decided to carry out more reactions to obtain a more significant amount of product and to be able to purify it.

Subsequently, two reactions were performed with each oligonucleotide: 5R2, 3F1, and 3F2. These reactions were run on a 1% agarose gel to observe the amplification bands of the product.

Once the possible product bands were observed, they were excised from the gel, and the products were extracted by electroelution for purification. The recovered products were run on a new 1% agarose gel to observe their quantity and integrity. It was observed that only the amplified product with 5R2, corresponding to the 5’ region, could be recovered, while those amplified with 3F1 and 3F2 were lost during the recovery and purification process.

Two more 3’ RACE reactions were performed for each oligonucleotide: 3F1 and 3F2. The reactions were run on a now 2% agarose gel to avoid curling of the loaded products on the gel. It was observed that there was no amplification in any of the reactions carried out. More reactions continued, changing the hybridization temperature and the synthesis of new cDNA to use in said reactions, but they could not get amplified.

Sequencing of the regions obtained

The amplified and purified fragments of the central and 5’ regions were sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Austin, TX, USA) and analyzed by capillary electrophoresis in a 310 Genetic sequencer. ABI PRISM Analyzer (Applied Biosystems, Foster City, CA, USA).

The sequences obtained (Figure 1) were analyzed to construct the sequence obtained. This construct consists of 1155 sequenced bp, of which 65 are in the possible UTR region, and 1090 bp are located ahead of the translation start site.

The complete sequence obtained was compared using the Multiple Sequence Alignment by CLUSTALW online tool (Institute for Chemical Research, Kyoto University, Uji, Kyoto 611-0011, Japan), with the sequence predicted for the NR5A1/SF1 cDNA (Figure 2), obtaining an alignment score of 94.24%.


The complexity of HG is evident. Expression of CYP450scc and 5α-reductases has been reported in hamster HG [14]. Androgen and estrogen receptors are known to exist in rat and hamster HG, suggesting that both testosterone and 5α-dihydrotestosterone affect secretory activity, as in the dimorphism of HG. In addition to the already known correlation between estrogens and the content of porphyrins in HG [15], member 2 of the G superfamily of the ATP-binding cassette (ABCG2) has been identified as involved in the regulation of the protoporphyrin IX transporter and other heme biosynthesis intermediates, which exhibits high expression in HG, with a dimorphic pattern, where females show greater expression than males [16-18].

The SOX9 protein, which can promote lipogenesis, is also expressed in HG, presenting a dimorphic expression being more significant in males than in females, suggesting that sex steroids may regulate this differential expression.

DAX1 is essential for differentiation during embryogenesis and is also expressed in HG but without showing sexual dimorphic expression. However, in adrenal glands, it presents a greater expression with a dimorphic behavior, being higher in females than in males, suggesting that sex steroids may control its activity. In addition, previous studies propose that DAX1 may be a protagonist in the differentiation, maintenance, and metabolism of HG in both sexes, with the interaction of other members of the nuclear receptor superfamily, such as NR5A1/SF1 and NR5A2.

Only part of NR5A1/SF1 has been sequenced, but the segment shows considerable similarity with the available sequence prediction. Even so, with the data obtained at the moment, it is impossible to know if NR5A1/SF1 has a differential expression in the Harderian gland and peripheral, steroidogenic, and nonsteroidogenic tissues. For this result, it is necessary to obtain and completely sequence the cDNA corresponding to NR5A1/SF1.

  1. Kanimozhi V, Palanivel K, Akbarsha MA, Kadalmani B. Molecular mechanisms of tributyltin-induced alterations in cholesterol homeostasis and steroidogenesis in hamster testis: In vivo and in vitro studies. J Cell Biochem. 2018; 119: 4021-37.
  2. Selvaraj V, Stocco DM, Clark BJ. Current knowledge on the acute regulation of steroidogenesis. Biol Reprod. 2018; 99: 13-26.
  3. Ruggiero C, Doghman M, Lalli E. NR5A1 (nuclear receptor subfamily 5, group A, member 1). Atlas Genet Cytogenet Oncol Haematol. 2015; 19: 522-534.
  4. Fabbri-Scallet H, de Sousa LM, Maciel-Guerra AT, Guerra-Junior G, de Mello MP. Mutation update for the NR5A1 gene involved in DSD and infertility. Hum Mutat. 2020; 41: 58-68.
  5. Anamthathmakula P, Miryala CSJ, Moreci RS, Kyathanahalli C, Hassan SS, Condon JC, et al. Steroidogenic Factor 1 (Nr5a1) is Required for Sertoli Cell Survival Post Sex Determination. Sci Rep. 2019; 9: 4452.
  6. Morohashi KI, Inoue M, Baba T. Coordination of Multiple Cellular Processes by NR5A1/Nr5a1. Endocrinol Metab (Seoul). 2020; 35: 756-64.
  7. Lalli E, Doghman M, Latre de Late P, El Wakil A, Mus-Veteau I. Beyond steroidogenesis: novel target genes for SF-1 discovered by genomics. Mol Cell Endocrinol. 2013; 371: 154-9.
  8. Lourenco D, Brauner R, Lin L, De Perdigo A, Weryha G, Muresan M, et al. Mutations in NR5A1 associated with ovarian insufficiency. N Engl J Med. 2009; 360: 1200-10.
  9. Payne AP. The harderian gland: a tercentennial review. J Anat. 1994; 185: 1-49.
  10. Chieffi G, Baccari GC, Di Matteo L, d’Istria M, Minucci S, Varriale B. Cell biology of the harderian gland. Int Rev Cytol. 1996; 168: 1-80.
  11. Hussein OA, Elgamal DA, Elgayar SA. Structure of the secretory cells of male and female adult guinea pigs Harderian gland. Tissue Cell. 2015; 47: 323-35.
  12. Santillo A, Chieffi Baccari G, Minucci S, Falvo S, Venditti M, Di Matteo L. The Harderian gland: Endocrine function and hormonal control. Gen Comp Endocrinol. 2020; 297: 113548.
  13. Falvo S, Chieffi Baccaria G, Spaziano G, Rosati L, Venditti M, Di Fiore MM, et al. StAR protein and steroidogenic enzyme expressions in the rat Harderian gland. C R Biol. 2018; 341: 160-6.
  14. Ramos L, Chavez B, Vilchis F. Cloning and differential expression of steroid 5 alpha-reductase type 1 (Srd5a1) and type 2 (Srd5a2) from the Harderian glands of hamsters. Gen Comp Endocrinol. 2010; 166: 388-95.
  15. Falvo S, Chieffi Baccaria G, Spaziano G, Rosati L, Venditti M, Di Fiore MM, et al. StAR protein and steroidogenic enzyme expressions in the rat Harderian gland. C R Biol. 2018; 341: 160-6.
  16. Mares L, Vilchis F, Chavez B, Ramos L. Expression and regulation of ABCG2/BCRP1 by sex steroids in the Harderian gland of the Syrian hamster (Mesocricetus auratus). C R Biol. 2019; 342: 279-89.
  17. Mares L, Ramos L. Harderian SOX9: Molecular characterization and its dimorphic expression in hamster. Comp Biochem Physiol A Mol Integr Physiol. 2021; 258: 110981.
  18. Ramos L, Mares L. Hamster DAX1: Molecular insights, specific expression, and its role in the Harderian gland. Comp Biochem Physiol A Mol Integr Physiol. 2021; 263: 111096.
Received : 03 Apr 2023
Accepted : 28 Mar 2023
Published : 29 Mar 2023
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X